209 related articles for article (PubMed ID: 31428518)
1. T cells engrafted with a UniCAR 28/z outperform UniCAR BB/z-transduced T cells in the face of regulatory T cell-mediated immunosuppression.
Kegler A; Koristka S; Bergmann R; Berndt N; Arndt C; Feldmann A; Hoffmann A; Bornhäuser M; Schmitz M; Bachmann MP
Oncoimmunology; 2019; 8(9):e1621676. PubMed ID: 31428518
[TBL] [Abstract][Full Text] [Related]
2. Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology.
Koristka S; Kegler A; Bergmann R; Arndt C; Feldmann A; Albert S; Cartellieri M; Ehninger A; Ehninger G; Middeke JM; Bornhäuser M; Schmitz M; Pietzsch J; Akgün K; Ziemssen T; Steinbach J; Bachmann MP
J Autoimmun; 2018 Jun; 90():116-131. PubMed ID: 29503042
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML.
Meyer JE; Loff S; Dietrich J; Spehr J; Jurado Jiménez G; von Bonin M; Ehninger G; Cartellieri M; Ehninger A
Oncoimmunology; 2021; 10(1):1945804. PubMed ID: 34290907
[TBL] [Abstract][Full Text] [Related]
4. Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts.
Suryadevara CM; Desai R; Farber SH; Choi BD; Swartz AM; Shen SH; Gedeon PC; Snyder DJ; Herndon JE; Healy P; Reap EA; Archer GE; Fecci PE; Sampson JH; Sanchez-Perez L
Clin Cancer Res; 2019 Jan; 25(1):358-368. PubMed ID: 30425092
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor costimulation domains modulate human regulatory T cell function.
Boroughs AC; Larson RC; Choi BD; Bouffard AA; Riley LS; Schiferle E; Kulkarni AS; Cetrulo CL; Ting D; Blazar BR; Demehri S; Maus MV
JCI Insight; 2019 Mar; 5(8):. PubMed ID: 30869654
[TBL] [Abstract][Full Text] [Related]
6. Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity.
Li W; Guo L; Rathi P; Marinova E; Gao X; Wu MF; Liu H; Dotti G; Gottschalk S; Metelitsa LS; Heczey A
Hum Gene Ther; 2017 May; 28(5):437-448. PubMed ID: 27530312
[TBL] [Abstract][Full Text] [Related]
7. Highly Efficient Targeting of EGFR-Expressing Tumor Cells with UniCAR T Cells via Target Modules Based on Cetuximab
Jureczek J; Feldmann A; Bergmann R; Arndt C; Berndt N; Koristka S; Loureiro LR; Mitwasi N; Hoffmann A; Kegler A; Bartsch T; Bachmann M
Onco Targets Ther; 2020; 13():5515-5527. PubMed ID: 32606767
[TBL] [Abstract][Full Text] [Related]
8. CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activation.
Kofler DM; Chmielewski M; Rappl G; Hombach A; Riet T; Schmidt A; Hombach AA; Wendtner CM; Abken H
Mol Ther; 2011 Apr; 19(4):760-7. PubMed ID: 21326215
[TBL] [Abstract][Full Text] [Related]
9. UniCAR T cell immunotherapy enables efficient elimination of radioresistant cancer cells.
Arndt C; Loureiro LR; Feldmann A; Jureczek J; Bergmann R; Máthé D; Hegedüs N; Berndt N; Koristka S; Mitwasi N; Fasslrinner F; Lamprecht C; Kegler A; Hoffmann A; Bartsch T; Köseer AS; Egan G; Schmitz M; Hořejší V; Krause M; Dubrovska A; Bachmann M
Oncoimmunology; 2020; 9(1):1743036. PubMed ID: 32426176
[TBL] [Abstract][Full Text] [Related]
10. Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies.
Mamonkin M; Mukherjee M; Srinivasan M; Sharma S; Gomes-Silva D; Mo F; Krenciute G; Orange JS; Brenner MK
Cancer Immunol Res; 2018 Jan; 6(1):47-58. PubMed ID: 29079655
[TBL] [Abstract][Full Text] [Related]
11. IL13Rα2-targeted third-generation CAR-T cells with CD28 transmembrane domain mediate the best anti-glioblastoma efficacy.
Gu A; Bai Y; Zhang C; Xu C; An Z; Zhang Y; Zhong SH; Hu Y; Zhong X
Cancer Immunol Immunother; 2023 Jul; 72(7):2393-2403. PubMed ID: 36991262
[TBL] [Abstract][Full Text] [Related]
12. Tregs integrate native and CAR-mediated costimulatory signals for control of allograft rejection.
Rosado-Sánchez I; Haque M; Salim K; Speck M; Fung VC; Boardman DA; Mojibian M; Raimondi G; Levings MK
JCI Insight; 2023 Oct; 8(19):. PubMed ID: 37669115
[TBL] [Abstract][Full Text] [Related]
13. Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells.
Dawson NAJ; Rosado-Sánchez I; Novakovsky GE; Fung VCW; Huang Q; McIver E; Sun G; Gillies J; Speck M; Orban PC; Mojibian M; Levings MK
Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32817364
[TBL] [Abstract][Full Text] [Related]
14. CD28 and 41BB Costimulatory Domains Alone or in Combination Differentially Influence Cell Surface Dynamics and Organization of Chimeric Antigen Receptors and Early Activation of CAR T Cells.
Mezősi-Csaplár M; Szöőr Á; Vereb G
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370693
[TBL] [Abstract][Full Text] [Related]
15. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells.
Hombach AA; Heiders J; Foppe M; Chmielewski M; Abken H
Oncoimmunology; 2012 Jul; 1(4):458-466. PubMed ID: 22754764
[TBL] [Abstract][Full Text] [Related]
16. Targeting CD10 on B-Cell Leukemia Using the Universal CAR T-Cell Platform (UniCAR).
Mitwasi N; Arndt C; Loureiro LR; Kegler A; Fasslrinner F; Berndt N; Bergmann R; Hořejší V; Rössig C; Bachmann M; Feldmann A
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563312
[TBL] [Abstract][Full Text] [Related]
17. A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform.
Albert S; Arndt C; Feldmann A; Bergmann R; Bachmann D; Koristka S; Ludwig F; Ziller-Walter P; Kegler A; Gärtner S; Schmitz M; Ehninger A; Cartellieri M; Ehninger G; Pietzsch HJ; Pietzsch J; Steinbach J; Bachmann M
Oncoimmunology; 2017; 6(4):e1287246. PubMed ID: 28507794
[TBL] [Abstract][Full Text] [Related]
18. Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia.
Loff S; Dietrich J; Meyer JE; Riewaldt J; Spehr J; von Bonin M; Gründer C; Swayampakula M; Franke K; Feldmann A; Bachmann M; Ehninger G; Ehninger A; Cartellieri M
Mol Ther Oncolytics; 2020 Jun; 17():408-420. PubMed ID: 32462078
[TBL] [Abstract][Full Text] [Related]
19. 4-1BB enhancement of CAR T function requires NF-κB and TRAFs.
Li G; Boucher JC; Kotani H; Park K; Zhang Y; Shrestha B; Wang X; Guan L; Beatty N; Abate-Daga D; Davila ML
JCI Insight; 2018 Sep; 3(18):. PubMed ID: 30232281
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model.
Pishali Bejestani E; Cartellieri M; Bergmann R; Ehninger A; Loff S; Kramer M; Spehr J; Dietrich A; Feldmann A; Albert S; Wermke M; Baumann M; Krause M; Bornhäuser M; Ehninger G; Bachmann M; von Bonin M
Oncoimmunology; 2017; 6(10):e1342909. PubMed ID: 29123951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
